Phuturdex › Diseases › B-cell leukemia
Drugs in development · updated 30 October 2026
B-cell leukemia: drugs in development
As of 30 October 2026 there are 35 active clinical trials (recruiting or ongoing, phases I–III) on 49 drugs for b-cell leukemia. 18 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| SurovatamigAZD0486 | III | 2 | NCT07509151 |
| Chemoimmunotherapy | III | 1 | NCT03836261 |
| Rocbrutinib | III | 1 | NCT07342478 |
| CD19 | I–II | 2 | NCT05442515 |
| Nemtabrutinib | I–II | 2 | NCT03162536 |
| AVM0703 | I–II | 1 | NCT04329728 |
| AZD5492 | I–II | 1 | NCT06542250 |
| CD10 | I–II | 1 | NCT04016129 |
| CD123 | I–II | 1 | NCT04016129 |
| CD20 | I–II | 1 | NCT04016129 |
| CD38 | I–II | 1 | NCT04016129 |
| MK-1045 | II | 1 | NCT07709000 |
| MS-553 | I–II | 1 | NCT06979076 |
| ACY-1215 | I | 1 | NCT02787369 |
| CLIC-2201 | I | 1 | NCT06208735 |
| Lonitoclax | I | 1 | NCT06708897 |
| MGD024 | I | 1 | NCT05362773 |
| U96 | I | 1 | NCT07511426 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ObinutuzumabGazyva®, Gazyvaro® | III | 5 | NCT03836261 |
| IbrutinibPCI 32765, Imbruvica® | III | 4 | NCT05254743 |
| PirtobrutinibJaypirca® | III | 4 | NCT05254743 |
| VenetoclaxVentoclax, Venclexta® | III | 4 | NCT03836261 |
| AcalabrutinibACP-196, Calquence® | III | 3 | NCT03836261 |
| CyclophosphamideCyclophosphamid, Cytoxan | I–II | 8 | NCT06564038 |
| FludarabineFludara, FLUDARABIN | I–II | 6 | NCT05442515 |
| MelphalanEvomela®, Hepzato® | II | 3 | NCT06001385 |
| MesnaUromitexan, Mesnex® | I–II | 3 | NCT03573700 |
| TacrolimusEnvarsus XR, Prograf® | II | 3 | NCT06001385 |
| ZanubrutinibBGB-3111, Brukinsa® | II | 3 | NCT07899398 |
| BusulfanBusulphan, Busulfex® | II | 2 | NCT06001385 |
| DoxorubicinAdriamycin, Doxorubincin | I–II | 2 | NCT06564038 |
| Mycophenolate MofetilMycophenolate, Cellcept | II | 2 | NCT06001385 |
| RituximabRuxience, Rituxan | I–II | 2 | NCT06564038 |
Sorted by most advanced phase and number of active trials. Showing 15 of 31 drugs.
All 49 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Chronic lymphocytic leukemia 137 drugs
- Non-Hodgkin lymphoma 269 drugs
- Mantle cell lymphoma 108 drugs
- Follicular lymphoma 144 drugs
- Diffuse large B-cell lymphoma 177 drugs
- Lymphoma, B-Cell, Marginal Zone 86 drugs
- Precursor lymphoblastic lymphoma/leukemia 163 drugs
- B-cell lymphoma 152 drugs
- Lymphoma 252 drugs
- Leukemia 153 drugs
- Waldenstrom Macroglobulinemia 51 drugs
- Acute myeloid leukemia 314 drugs
Broader categories
- Neoplasm 671 drugs
- Hematologic Diseases 57 drugs
- Immune System Diseases 54 drugs
- Lymphatic system disease 20 drugs
- Immunoproliferative disorder 16 drugs
- Lymphoproliferative disorders 51 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D015448 “Leukemia, B-Cell”.